Clinical trial
A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus
NCT04127747 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- August 18, 2020
- Completion date
- July 1, 2023
- Enrollment
- 110 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.